Windtree Therapeutics Stock (NASDAQ: WINT)

Windtree Therapeutics (NASDAQ:WINT) Stock, Quote.Headers.trade-ideas

Windtree Therapeutics

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

EFSH

GLMD

HCTI

IOBT

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

pharmaceutical ARDX Ardelyx

Windtree Therapeutics shares are trading higher Wednesday after the company completed enrollment of its SEISMiC Extension Phase 2b study of istaroxime.

What&#39;s Going On With Windtree Therapeutics Stock Wednesday?

Intraday Update

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics Inc

Windtree Therapeutics Inc arrants (25/03/2026)

WINTO GROUP HLDGS LTD by WINTO GROUP HLDGS LTD.

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

Deutsche Bank analyst Bryan Keane maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and raises the price target from $74 to $94.

Price Target

Analyst Ratings

PYPL

Deutsche Bank Maintains Buy on PayPal Holdings, Raises Price Target to $94

WIIM

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon shares are trading lower after the company said it is proceeding with an approved reverse stock split.

BMO Capital analyst Daniel Jester initiates coverage on OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Outperform rating and announces Price Target of $38.

Initiation

BMO Capital Initiates Coverage On OneStream with Outperform Rating, Announces Price Target of $38

General Motors shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform.

Signing Day Sports shares are trading higher after the company announced that it provided an update regarding its financial position and its plans to acquire Dear Cashmere Group Holding Company, doing business as Swifty Global.

ULTA

Ulta Beauty shares are trading lower after TD Cowen downgraded the stock to Hold.

Baird analyst David Koning maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $186 to $200.

Baird Maintains Outperform on Fiserv, Raises Price Target to $200

Wheels Up shares are trading higher after the company announced that approximately 97.2% of lead investor shares will remain subject to a lock-up restriction until September 20, 2025.

Baird analyst Peter Arment maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Outperform and raises the price target from $22 to $35.

KTOS

Baird Maintains Outperform on Kratos Defense & Security, Raises Price Target to $35

BDTX

Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.

In a recent turn of events, the United States has directly cautioned Israel against escalating hostilities with Hezbollah, as the two sides engage in intense cross-border exchanges. The U.S. has urged Israel to seek diplomatic solutions, emphasizing the potential risks of a full-scale land war.
What Happened: On Sunday, Israeli forces and Hezbollah militants clashed in some of the most severe confrontations since Oct. 7, Financial Times <a href="https://www.ft.com/content/2bb03f05-c3d5-4f3f-99e3-56f541f51769">reported</a> on Monday. The escalating violence has raised concerns about the situation spiraling into a full-scale war.
John Kirby, a spokesperson for the U.S. National Security Council, cautioned Israel against escalating the conflict. He stated that there are &#8220;better ways&#8221; to ensure the safety of Israeli citizens than through war or further escalation. President Joe Biden assured that his administration would do everything possible to prevent a wider war.
Despite international calls for de-escalation, Israeli Prime Minister Benjamin Netanyahu has pledged to maintain military pressure on Hezbollah. The situation has become increasingly tense, with the recent hostilities resulting in a significant rise in casualties.
See Also: <a href="https://www.benzinga.com/news/24/09/40970828/data-scientists-election-prediction-kamala-harris-receives-historic-endorsement-from-magazine-elon-m?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist&#8217;s Election Prediction, Kamala Harris Receives Historic Endorsement From Magazine, Elon Musk Suggests Warren Buffett Is Preparing For A Harris Win And More: Top Political Update This Week</a>
On Monday, Israeli airstrikes in Lebanon led to 30 deaths and over 300 injuries, as per CNN. This escalation follows a series of events, including Hezbollah&#8217;s rocket attacks on Israel and the detonation of the group&#8217;s communication devices, which Hezbollah blames on Israel. The recent violence has led to fears of a potential full-scale war.
Why It Matters: The recent violence adds to the <a href="https://www.benzinga.com/news/24/09/40924166/hezbollah-hit-in-new-round-of-explosions-across-lebanon-casualties-climb">already tense situation</a> in the region. Just last week, Lebanon experienced a second wave of deadly explosions targeting Hezbollah operatives, following a massive wave of pager explosions that killed 12 people and injured nearly 2,800 more. The second round of explosions killed at least nine people and injured over 300, further exacerbating the situation in Lebanon.
Meanwhile, U.S. Senator Lindsey Graham has called for a new <a href="https://www.benzinga.com/news/24/09/40973072/lindsey-graham-says-either-saudi-arabia-recogonizes-israel-or-tel-aviv-targets-tehran-we-need-game-c">approach to Middle East policy,</a> advocating for either a &#8220;game-changing peace&#8221; or a &#8220;game-changing military strategy.&#8221; Graham suggested that a significant shift in strategy is needed, either through Saudi Arabia recognizing Israel, or Israel taking military action against Iran.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo by Ilin Sergey on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Global

General

US Warns Israel Against Opening A Full-Blown War Against Hezbollah As Air Strikes Kill 30 In Lebanon

Monday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator&#8217;s choice of chemotherapy.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html" rel="noreferrer noopener">study</a> did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.
The study previously met the dual primary endpoint of progression-free survival.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40793946/astrazeneca-ceo-pascal-soriot-updates-on-chinese-compliance-probe-and-lung-cancer-drug-trial-resu" rel="noreferrer noopener">AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results</a>.
An improvement in patient-reported outcomes was also seen.
The safety profile of datopotamab deruxtecan was consistent with that observed in the previous analysis, including lower rates of Grade 3 or higher treatment-related adverse events compared to chemotherapy, and no new safety concerns were identified.
All-grade interstitial lung disease (ILD) rates remained low, and no new Grade 3 or higher ILD events were observed.
With multiple antibody-drug conjugates (ADCs) approved during the trial, including&nbsp;Enhertu (trastuzumab deruxtecan), subsequent treatment following patients&#8217; disease progression or treatment discontinuation is likely to have affected survival results.
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd ADC discovered by Daiichi Sankyo Ltd&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) and being jointly developed by AstraZeneca and Daiichi Sankyo.
Earlier this month, AstraZeneca&nbsp;shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40791315/astrazenecas-investigational-cancer-drug-disappoints-in-late-stage-lung-cancer-trial" rel="noreferrer noopener">one prior line of therapy</a>.
In the overall trial population, OS results numerically favored datopotamab deruxtecan compared to docetaxel (12.9 vs. 11.8 months) but did not reach statistical significance.
Friday, the FDA <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html" rel="noreferrer noopener">approved</a> AstraZeneca&#8217;s FluMist as the only self-administered influenza vaccine.&nbsp;
FluMist, a needle-free nasal spray, was approved for self-administration by adults up to 49 years of age or for parent/caregiver administration to individuals 2-17 years of age.
Once available, individuals 18 and older can have FluMist delivered directly to their homes via FluMist Home.
Price Action: AZN stock is down 1.86% at $76.92 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" target="_blank" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>.</li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Large Cap

Health Care

DSKYF

DSNKY

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients

Baird analyst Ben Kallo maintains Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) with a Outperform and raises the price target from $32 to $42.

AMRC

Baird Maintains Outperform on Ameresco, Raises Price Target to $42

BHVN

Biohaven shares are trading higher after the company announced its study of Troriluzole for the treatment of spinocerebellar ataxia in achieved the primary endpoint.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>)</h3>
<ul>
<li>Dividend Yield: 5.78%</li>
<li>Jefferies analyst Omar Nokta maintained a Buy rating and raised the price target from $22 to $25 on Aug. 20. This analyst has an accuracy rate of 73%.</li>
<li>JP Morgan analyst Samuel Bland maintained a Neutral rating and cut the price target from $9.3 to $9.25 on March 22. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Aug. 19, ZIM Integrated Shipping Services reported better-than-expected second-quarter financial results and raised its FY24 guidance.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> latest ZIM news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073915/image-174.png" alt="" class="wp-image-560853" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073915/image-174.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073915/image-174-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073915/image-174-768x717.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Genco Shipping &amp; Trading Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>)</h3>
<ul>
<li>Dividend Yield: 7.57%</li>
<li>B. Riley Securities analyst Liam Burke maintained a Buy rating and raised the price target from $27 to $30 on May 10. This analyst has an accuracy rate of 62%</li>
<li>Jefferies analyst Omar Nokta maintained a Buy rating and increased the price target from $26 to $27 on May 9. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Sept. 10, Genco Shipping &amp; Trading enhanced Dividend Policy to increase cash distributable to shareholders.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> trend in GNK stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073956/image-175.png" alt="" class="wp-image-560854" style="width:692px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073956/image-175.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073956/image-175-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23073956/image-175-768x704.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.32%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold and cut the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 75%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating and raised the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 82%.</li>
<li>Recent News: On Aug. 8, Karat Packaging reported worse-than-expected second-quarter financial results.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">breakout in KRT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23074037/image-176.png" alt="" class="wp-image-560857" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23074037/image-176.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23074037/image-176-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23074037/image-176-768x728.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $96 to $92.

APLS

Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $92

Mativ Holdings, Inc. ("Mativ" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATV#NYSE">MATV</a>) today announced that it has commenced a private offering that is exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), subject to market and other conditions, of $400,000,000 in aggregate principal amount of senior notes due 2029 (the "Notes"). The Notes will be senior unsecured obligations of the Company and will be guaranteed by each of the Company's existing and future wholly owned subsidiaries that is a borrower under or that guarantees obligations under its credit agreement or that guarantees certain other indebtedness, subject to certain exceptions. The Company intends to use the net proceeds from the offering (i) to redeem its 6.875% Senior Notes due 2026 ("2026 Notes") and (ii) to repay approximately $43 million aggregate principal amount of outstanding borrowings under the term loan B facility under its credit agreement.
The Notes and the related guarantees will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements under the Securities Act and any applicable securities laws of any other jurisdiction.

Offerings

MATV

Mativ Holdings To Raie $400M Via Proposed Private Offering of Senior Notes To Repay Debt

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the International Congress of Parkinson's Disease and Movement Disorders&#xAE; (MDS) taking place September 27 – October 1, 2024 in Philadelphia, PA.
"The MDS Congress promises to be an exceptional medical meeting for Alterity with multiple presentations showcasing our progress this year. Highlights for us include oral presentations on both of our Phase 2 clinical programs including the acceptance of our late-breaking interim data from our ATH434-202 trial in participants with advanced multiple system atrophy (MSA)," commented, David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics to Present Key Phase 2 Data at Parkinson's Congress

Bowman Consulting Group Ltd. (the Company or Bowman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services firm delivering infrastructure design solutions and project management services to customers who own, develop and maintain the built environment, has been contracted by the Illinois Department of Transportation (IDOT) to provide corridor management and design services for a 15.6-mile corridor of I-55.
"We are excited to start working on the highly impactful and innovative I-55 corridor assignment," said Gary Bowman, chairman and CEO of Bowman. "This is one of several awards where we've been anticipating and planning for a final contract and notice to proceed for several months. We had the necessary resources for the assignment in place, so we were able to mobilize quickly and immediately commence work on the project. Our transportation practice has unparalleled experience with the complexities of large-scale infrastructure projects in Illinois, and we appreciate this opportunity to help IDOT improve and modernize one of the most heavily traveled expressways in the state for its constituents."
Corridor management is an innovative approach to transportation system management whereby public agencies and private contractors commit to working together to manage a transportation corridor holistically rather than the more traditional approach of managing individual assets discretely. This contract is one of a few design management corridor contracts to be released from IDOT and is a key component of the state's $45 billion Rebuild Illinois infrastructure investment program strategy.
Under this engagement, Bowman will manage all projects within the highly trafficked stretch of I-55, which connects Chicago to its southwest suburbs, a corridor that transits over 100,000 vehicles daily. Additionally, Bowman will prepare bridge repair plans for 16 bridges within the corridor, as well as develop roadway improvement plans of the expressway. These enhancements have been identified as key to improving safety, reducing congestion and extending the lifespan of Illinois' transportation infrastructure.

Government

Regulations

BWMN

Bowman Consulting Lands Major I-55 Corridor Management Contract with Illinois Department of Transportation (IDOT)

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the completion of enrollment in Cohort 2 of the ongoing Phase 1b clinical trial of LTI-03 in IPF patients.
&nbsp;
The last patient was enrolled in mid-September, with a total of 24 patients enrolled in the trial. Eligible patients are randomly assigned (3:1) to receive either inhaled LTI-03 or placebo. The primary objective of the trial is to evaluate the safety and tolerability of LTI-03 in patients with IPF after treatment for 14 consecutive days, with measurement of multiple protein biomarkers as exploratory endpoints.
"We are pleased to have completed enrollment in the high-dose cohort of our Phase 1b clinical trial and grateful to all participating patients and investigators," said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. "Following the positive trend observed in the low-dose cohort, we are excited to assess the safety, tolerability and biomarkers of 5 mg twice daily of inhaled LTI-03 and expect to report topline data in the near term."
In May 2024, the Company <a href="https://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-announces-positive-data-cohort-1-phase-1b">announced positive data</a> from Cohort 1 evaluating low-dose LTI-03 (2.5 mg BID). Following inhaled administration of low-dose LTI-03 in 12 patients, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among multiple profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from three biomarkers that was statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF.
About the Phase 1 Clinical Trial of LTI-03
The Phase 1b clinical trial of LTI-03 is a randomized, double-blind, placebo controlled, multi-center, dose escalation trial in patients recently diagnosed with IPF that have not received prior treatment with anti-fibrotic agents for at least two months (<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05954988">NCT05954988</a>). Eligible patients are randomly assigned (3:1) to receive one of two doses of inhaled LTI-03 or placebo. The primary objective of the trial is to investigate the safety and tolerability of LTI-03 in patients with IPF after treatment for 14 consecutive days, with measurement of multiple protein biomarkers as exploratory endpoints.

ALRN

Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon

The latest update is out from Windtree Therapeutics (WINT). Windtree Therapeutics, Inc. has entered into a Securities Purchase Agreement for a priv...

Windtree Therapeutics Raises Funds Through Strategic Securities Placement

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning as we check out all of the hottest news investors need to know about on Friday!



Moving stocks this morning are earnings reports, a clinical trial update, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Windtree Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) stock is rocketing close to 121% <a href="https://www.nasdaq.com/press-release/windtree-therapeutics-provides-update-istaroxime-clinical-development-and-upcoming">on a clinical trial update</a>.</li>



<li>BurgerFi International (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) shares are soaring more than 93% <a href="https://www.nasdaq.com/press-release/burgerfi-reaches-legal-settlement-agreement-lion-point-capital-lp-2024-07-25">on a settlement agreement</a>.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is surging over 65% on a <a href="https://www.nasdaq.com/press-release/carbon-revolution-supplies-carbon-fiber-wheels-chevrolet-corvette-zr1-2024-07-25">supply deal with Chevrolet</a>.</li>



<li>Everi (NYSE:<a href="https://investorplace.com/stock-quotes/evri-stock-quote/">EVRI</a>) shares are gaining more than 35% <a href="https://www.nasdaq.com/press-release/igts-gaming-and-digital-business-and-everi-be-acquired-simultaneously-apollo-funds">on an acquisition deal</a>.</li>



<li>Coursera (NYSE:<a href="https://investorplace.com/stock-quotes/cour-stock-quote/">COUR</a>) stock is increasing over 26% with its <a href="https://www.businesswire.com/news/home/20240725452896/en/Coursera-Reports-Second-Quarter-2024-Financial-Results">latest earnings report</a>.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) shares are rising more than 24% alongside heavy pre-market trading.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is heading over 21% higher with strong early morning trading.</li>



<li>Nova Minerals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVA#NASDAQ">NVA</a>) shares are climbing more than 20% <a href="https://www.tipranks.com/news/company-announcements/nova-minerals-issues-millions-of-new-warrants">after issuing new warrants</a>.</li>



<li>International Game Technology (NYSE:<a href="https://investorplace.com/stock-quotes/igt-stock-quote/">IGT</a>) stock is jumping over 20% alongside the <a href="https://www.prnewswire.com/news-releases/igts-gaming-and-digital-business-and-everi-to-be-acquired-simultaneously-by-apollo-funds-in-all-cash-transaction-302207429.html">Everi acquisition news</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are up more than 17% on Friday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NovaBay Pharmaceuticals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nby-stock-quote/">NBY</a>) stock is crashing more than 40% without any clear news this morning.</li>



<li>DexCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) shares are plummeting over 34% on <a href="https://www.nasdaq.com/press-release/dexcom-reports-second-quarter-2024-financial-results-updates-guidance-and-announces">poor Q2 results and a cut outlook</a>.</li>



<li>Advent Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/adn-stock-quote/">ADN</a>) stock is diving more than 33% despite a lack of news this morning.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are tumbling over 30% after <a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">rallying earlier this week</a>.</li>



<li>Zynex (NASDAQ:<a href="https://investorplace.com/stock-quotes/zyxi-stock-quote/">ZYXI</a>) stock is taking a nearly 23% beating with its <a href="https://www.nasdaq.com/press-release/zynex-reports-second-quarter-2024-financial-results-2024-07-25">Q2 earnings report</a>.</li>



<li>Ocean Power Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/optt-stock-quote/">OPTT</a>) shares are sliding more than 22% <a href="https://www.nasdaq.com/press-release/ocean-power-technologies-inc-announces-fourth-quarter-and-full-year-fiscal-2024">alongside its latest earnings report</a>.</li>



<li>Renovaro (NASDAQ:<a href="https://investorplace.com/stock-quotes/renb-stock-quote/">RENB</a>) stock is dropping over 18% without any obvious news to report.</li>



<li>Avinger (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgr-stock-quote/">AVGR</a>) shares are falling almost 15% this morning.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is decreasing 14% after rallying yesterday.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares close out our pre-market stock movers down more than 13.5% after jumping yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Windtree Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) stock is rocketing higher on Friday after the biotechnology company provided an update on its <a href="https://www.nasdaq.com/press-release/windtree-therapeutics-provides-update-istaroxime-clinical-development-and-upcoming">clinical trial of istaroxime</a>.



Windtree Therapeutics notes that it is expecting its Phase 2 Phase 2 SEISMiC Extension Study to complete enrollment within the company weeks. This is testing the use of istaroxime on SCAI Stage B early cardiogenic shock patients.



Windtree Therapeutics also notes that it will have topline data from this study ready be the end of the quarter. This builds on prior successful Phase 2 studies of istaroxime as the company plans for a Phase 3 clinical trial.



Additionally, Windtree Therapeutics is gearing up for a study of istaroxime to treat SCAI Stage C cardiogenic shock patients.&nbsp;These are more ill than those with SCAI Stage B early cardiogenic shock.



Windtree Therapeutics chairman and CEO Craig Fraser said the following.




&ldquo;We are pleased with our progress in clinical development because of the importance of the high unmet needs in the patient populations we are studying.&rdquo;




<h2>WINT Stock Movement on Friday</h2>



With all of this news comes heavy trading of WINT stock. That has more than 5 million of the company&rsquo;s shares changing hands. This is well above its daily average trading volume of about 50,000 shares.



WINT stock is up 116% as of Friday morning.



Investors will want to keep reading for more of the most recent stock market news today!



We have all of the hottest stock market news ready to go on Friday! That includes the biggest pre-market stock movers this morning and other recent happenings. You can catch up on all of this below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-26th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/07/ticker-mix-up-the-container-store-tcs-stock-soars-despite-no-clear-news/">Ticker Mix-Up? The Container Store (TCS) Stock Soars Despite No Clear News.</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-elon-musk-says-tesla-board-will-review-xai-investment-proposal/">TSLA Stock: Elon Musk Says Tesla Board Will Review xAI Investment Proposal</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-windtree-therapeutics-wint-stock-up-116-today/">Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BurgerFi International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is taking off on Friday after the fast-casual food company announced a settlement agreement with Lion Point Capital, LP.



This will have BurgerFi International paying $1.35 million to Lion Point Capital, LP. It will also see it issue the company 300,000 shares of Series A Preferred Stock.



This agreement will close out the current litigation between BurgerFi International and Lion Point Capital, LP. That lawsuit included allegations that BurgerFi International failed to timely register Lion Point Capital, LP&rsquo;s, violating a registration rights agreement.



David Heidecorn, chairman of the board at BurgerFi International, said the following about the settlement news.




&ldquo;We are pleased to be putting this litigation matter with Lion Point firmly behind us. Our intention is to continue to explore strategic alternatives that we believe would be in the best interests of the Company and its stakeholders, as previously disclosed.&rdquo;




<h2>BFI Stock Movement Today</h2>



Today&rsquo;s settlement news brings with it heavy trading of BFI shares. That has more than 14 million shares changing hands as of this writing. This is well above its daily average trading volume of about 564,000 shares.



BFI stock is up 71.4% as of Friday morning.



There are plenty more stock market stories worth reading about below!



We have all of the hottest stock market news available on Friday! Among that is what has shares of Windtree Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) stock up, the biggest pre-market stock movers and more. All of this news is ready at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-windtree-therapeutics-wint-stock-up-116-today/">Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-26th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-zai-lab-zlab-stock-is-a-possible-hidden-gem/">Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">Why Is BurgerFi International (BFI) Stock Up 71% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is BurgerFi International (BFI) Stock Up 71% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
DexCom&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) stock is falling on Friday after the company released its earnings report for Q2 2024.



DexCom starts its earnings report with <a href="https://www.nasdaq.com/press-release/dexcom-reports-second-quarter-2024-financial-results-updates-guidance-and-announces">adjusted earnings per share of 43 cents</a>. That&rsquo;s better than Wall Street&rsquo;s estimate of 39 cents per share. It&rsquo;s also an improvement over its adjusted EPS of 34 cents in the same period of the year prior.



However, the company&rsquo;s revenue of $1 billion failed to impress. It doesn&rsquo;t stack up to analysts&rsquo; estimate of $1.04 billion. Even if its a 15% increase year-over-year from $871.3 million.



Dexcom chairman, president and CEO Kevin Sayer said the following about the earnings report.




&ldquo;While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards. We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth.&rdquo;




<h2>Guidance Cut Hits DXCM Stock Today</h2>



DXCM also updated its guidance in its latest earnings report. This has it expecting Q3 2024 revenue to range from $975 million to $1 billion. That would miss Wall Street&rsquo;s estimate of $1.15 billion in revenue.



For the full year of 2024, DexCom&nbsp;is predicting revenue of $4 to $4.05 billion. At the midpoint that would miss analysts&rsquo; estimate of $4.33 billion for the year.



DXCM stock is down 38.1% as of Friday morning with some 1.3 million shares traded. Its daily average trading volume is still above that at about 2.7 million shares.



We have more of the most recent stock market stories traders need to know about on Friday!



That includes all of the hottest market news news available today! A few examples include what&rsquo;s happening with shares of BurgerFi International&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>), Zai Lab&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/zlab-stock-quote/">ZLAB</a>) and Windtree Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) stock&nbsp;this morning. You can catch up on this news at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">Why Is BurgerFi International (BFI) Stock Up 71% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-zai-lab-zlab-stock-is-a-possible-hidden-gem/">Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-windtree-therapeutics-wint-stock-up-116-today/">Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-dexcom-dxcm-stock-down-38-today/">Why Is DexCom (DXCM) Stock Down 38% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is DexCom (DXCM) Stock Down 38% Today?

Windtree Therapeutics (WINT) has provided an announcement. Windtree Therapeutics, Inc. has experienced a shift in its Board of Directors, with Dani...

Windtree Therapeutics Board Reshuffles, Appoints New Directors

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Windtree Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) just reported results for the first quarter of 2024.<ul><li>Windtree Therapeutics reported earnings per share of -$20.91.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/wint-stock-earnings-windtree-therapeutics-for-q1-of-2024/">WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024

Windtree Therapeutics GAAP EPS of -$20.91 misses by $18.64

Windtree Therapeutics files to sell 27.67M shares of common stock for holders

An announcement from Windtree Therapeutics ( ($WINT) ) is now available. The Company has been actively engaging in financial maneuvers, including e...

Windtree Therapeutics Expands Stock and Restructures Finances

AVGR

BLMZ

COUR

CREV

DXCM

EVRI

NMHI

OPTT

PAPL

RENB

SLNA

XCUR

ZLAB

ZPTA

ZYXI

Press Releases

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Earnings

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Windtree Therapeutics Announces Reverse Stock Split

Windtree Therapeutics Regains Compliance with Nasdaq

Financing

Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Management

Windtree Announces New Additions and Changes to Its Board of Directors

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Alzamend Neuro

Anitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Windtree Therapeutics

Windtree Therapeutics (WINT) Forecast

Windtree Therapeutics (NASDAQ:WINT) Stock, Quote.Headers.trade-ideas